Wealth Enhancement Advisory Services LLC Has $4.58 Million Holdings in Natera, Inc. $NTRA

Key Points

• Wealth Enhancement Advisory Services LLC increased its stake in Natera, Inc. by 46.4% in Q2, holding 28,323 shares worth $4.58 million after buying an additional 8,977 shares.
• Several analysts have issued positive ratings for Natera, with price targets up to $268.00, reflecting strong market confidence in the company's performance.
• Natera reported a quarterly revenue of $546.6 million, exceeding estimates, despite missing EPS expectations with a loss of ($0.74) per share.

Wealth Enhancement Advisory Services LLC boosted its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 46.4% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 28,323 shares of the medical research company's stock after purchasing an additional 8,977 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Natera were worth $4,582,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. HighPoint Advisor Group LLC boosted its stake in Natera by 30.8% during the 1st quarter. HighPoint Advisor Group LLC now owns 1,986 shares of the medical research company's stock valued at $308,000 after purchasing an additional 468 shares during the period. Amalgamated Bank lifted its holdings in shares of Natera by 9.8% during the first quarter. Amalgamated Bank now owns 8,293 shares of the medical research company's stock worth $1,173,000 after buying an additional 740 shares during the last quarter. Comerica Bank lifted its holdings in shares of Natera by 24.1% during the first quarter. Comerica Bank now owns 141,106 shares of the medical research company's stock worth $19,954,000 after buying an additional 27,379 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Natera by 32.3% during the first quarter. GAMMA Investing LLC now owns 848 shares of the medical research company's stock worth $120,000 after buying an additional 207 shares during the last quarter. Finally, Asset Management One Co. Ltd. acquired a new position in shares of Natera during the first quarter worth approximately $6,753,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently commented on NTRA shares. Stephens reiterated an "overweight" rating and set a $183.00 target price on shares of Natera in a research note on Friday, August 15th. Barclays reaffirmed an "overweight" rating and set a $210.00 price objective (up previously from $190.00) on shares of Natera in a research report on Friday, August 8th. Wells Fargo & Company assumed coverage on shares of Natera in a research report on Monday. They set an "equal weight" rating and a $175.00 price objective for the company. Royal Bank Of Canada set a $268.00 price target on Natera and gave the company an "outperform" rating in a report on Tuesday, September 2nd. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $220.00 price target (up previously from $210.00) on shares of Natera in a report on Monday, August 11th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $192.88.

Natera Stock Down 0.2%

NASDAQ:NTRA opened at $163.66 on Friday. Natera, Inc. has a 12-month low of $117.27 and a 12-month high of $183.00. The firm has a market capitalization of $22.46 billion, a PE ratio of -85.69 and a beta of 1.68. The firm has a 50-day moving average price of $158.39 and a 200 day moving average price of $155.85.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical research company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The company had revenue of $546.60 million during the quarter, compared to analyst estimates of $476.84 million. During the same period in the previous year, the company posted ($0.30) earnings per share. The company's quarterly revenue was up 32.2% on a year-over-year basis. Natera has set its FY 2025 guidance at EPS. On average, research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity

In related news, Director Gail Boxer Marcus sold 4,299 shares of the stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the sale, the director owned 8,118 shares in the company, valued at $1,358,628.48. This trade represents a 34.62% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Rowan E. Chapman sold 2,750 shares of the stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $166.99, for a total transaction of $459,222.50. Following the sale, the director owned 6,015 shares of the company's stock, valued at $1,004,444.85. This trade represents a 31.37% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 56,423 shares of company stock valued at $8,459,656. 5.63% of the stock is owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.